Narrow Results

Gliomas are tumors of the primary central nervous system associated with poor prognosis and high mortality. The 5-year survival rate of patients with gliomas received surgery combined with chemotherapy or radiotherapy does not exceed 5%. Although temozolomide is commonly used in the treatment of gliomas, the development of resistance limits its use. MicroRNAs are non-coding RNAs involved in numerous processes of glioma cells, such as proliferation, migration and apoptosis. MicroRNAs regulate cell cycle, PI3K/AKT signal pathway, and target apoptosis-related genes (e.g., BCL6), angiogenesis-related genes (e.g., VEGF) and other related genes to suppress gliomas. Evidence illustrates that microRNAs can regulate the sensitivity of gliomas to temozolomide, cisplatin, and carmustine, thereby enhancing the efficacy of these agents. Moreover, traditional Chinese medicine (e.g., tanshinone IIA, xanthohumol, and curcumin) exert antiglioma effects by regulating the expression of microRNAs, and then microRNAs inhibit gliomas through influencing the process of tumors by targeting certain genes. In this paper, the mechanisms through which microRNAs regulate the sensitivity of gliomas to therapeutic drugs are described, and traditional Chinese medicine that can suppress gliomas through microRNAs are discussed. This review aims to provide new insights into the traditional Chinese medicine treatment of gliomas.

Imagene Labs Introduces Region’s First Complete Genetics-Based Wellness Solutions.

ASLAN Pharmaceuticals and A*STAR Enter RON Antibody Licensing and Research Collaboration Agreement.

Hidden HIV Revealed: New Insights into Latent HIV Infections.

Agilent Technologies Introduces Transformational Technology for Gas Chromatography.

Merck Joins DiViNe Consortium to Address Low Yields, High Costs of Vaccine Purification Processes.

FEI Celebrates Shipment of 1,000th Helios DualBeam System.

miRNA-21 (miR-21) is a potential biomarker for the monitoring of diseases through its expression levels. Simple, portable and sensitive miR-21 detection of is advantageous for health monitoring in Point of Care Testing (POCT). Gold nanoparticles (AuNP) as excellent colorimetric sensors are widely used in the POCT. However, their low sensitivity is a limitation of their clinical use. Herein, we developed an AuNPs-based miR-21 assay with enzyme-assisted amplification reaction to construct the colorimetric platform capable of detecting as low as 0.1nM. In this platform, template ssDNA as a signal molecule could hybridize with ssDNA-modified AuNPs to generate the color reaction. The target miR-21 specifically hybridized to the template ssDNA, which was then cleaved by exonuclease III (Exo III) to release the target miR-21. As a trigger, miR-21 catalyzed the degradation of the template ssDNA to amplify the signal by Exo III. By hybridizing miR-21 and template ssDNA in the presence of Exo III, R-21 induced a significant decrease in the level of template ssDNA to reduce the aggregation of AuNPs. There is a clear color difference in the presence/absence of miR-21 in the assay. In this assay, the optimal concentration of templated ssDNA and Exo III were 100nM and 0.06U/$\mu$L in a 100$\mu$L detection system. The LoD for UV–Vis spectrum and colorimetric reaction were 0.1nM and 0.5nM, respectively. The detection system has good selectivity and can be used to detect miR-21 in the simulated saliva. It has great potential for application in biomedical research as well as in clinical diagnostics.

Long non-coding RNA (lncRNA) is a new class of endogenous molecules identified in recent years. Studies on the cancer transcriptome have identified a number of lncRNAs with distinct expression patterns in different types of cancer, indicating that this populous group of molecules can modulate cancer progression. In addition, advances in revealing the molecular principles of cancer-associated lncRNAs made them amenable for therapeutic intervention. Although more than 50,000 lncRNAs have been identified, their functions in cellular homeostasis and pathophysiological processes remain largely uncharacterized. In this review, we summarize cancer-related lncRNAs that have been identified in recent years and discuss their mechanistic roles as oncogenes or tumor suppressors. These findings provide insights into clinical application of lncRNAs as biomarkers or therapeutic targets.

Numerous crosstalk interactions between RNA-binding proteins (RBPs) and microRNAs (miRNAs) have been recently reported, unveiling the complexity and importance of gene expression modulation in health and disease. They control physiological processes such as stem cell maintenance, neuronal development or energetic metabolism, but are also responsible for pathological conditions, such as muscle waste and dystrophies, atherosclerosis, obesity and cancer. MiRNAs and RBPs are two of the well-studied post-transcriptional regulators and they may even reciprocally regulate themselves. MiRNAs can act on RBPs expression while RBPs modulate miRNA biogenesis, function and degradation. RBPs and miRNAs modulate mRNA expression at different levels, affecting their stability, splicing and translation efficiency through either competition for overlapping binding or modulation of mRNA structure by binding, but several other forms of interaction have been described. In this review, we will address the current bibliography regarding miRNA:RBP interactions and crosstalk events as well as their implications in health and disease.